Silodosin Dosage
This dosage information may not include all the information needed to use Silodosin safely and effectively. See additional information for Silodosin.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Benign Prostatic Hyperplasia
8 mg orally once a day with a meal
Renal Dose Adjustments
CrCl 50 to 80 mL/min: No adjustment recommended
CrCl 30 to 50 mL/min: 4 mg once a day with a meal
CrCl less than 30 mL/min: Contraindicated
Liver Dose Adjustments
Mild or moderate hepatic impairment: No adjustment recommended
Severe hepatic impairment (Child-Pugh score greater than or equal to 10): Contraindicated
Precautions
Concomitant use of silodosin and potent inhibitors of CYP450 3A4 (e.g., ketoconazole, clarithromycin, itraconazole, ritonavir) is contraindicated. Caution should be exercised and the patient monitored for adverse events when silodosin is coadministered with moderate inhibitors of CYP450 3A4 (e.g., diltiazem, erythromycin, verapamil).
Silodosin is a P-gp substrate and is not recommended for use in patients taking strong P-gp inhibitors (e.g., cyclosporine, ketoconazole).
Silodosin is not recommended for use with other alpha-blockers.
Since benign prostatic hyperplasia (BPH) and carcinoma of the prostate cause many of the same symptoms and may coexist, patients thought to have BPH should be screened for prostate cancer prior to starting therapy with silodosin.
Orthostatic hypotension, with or without symptoms (e.g., dizziness), and syncope may develop when beginning treatment with silodosin. Patients should be cautioned about driving, operating machinery, or performing hazardous tasks until they know how the drug affects them. This is especially important for the elderly and individuals with low blood pressure or taking antihypertensive medications.
Intraoperative floppy iris syndrome (IFIS) has been observed during cataract surgery in some patients on alpha-1 blockers or previously treated with alpha-1 blockers. Patients planning cataract surgery should inform their ophthalmologist that they are taking silodosin.
Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).
Dialysis
Data not available
